Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Non Operating Income (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Non Operating Income for 2 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 232.44% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $97032.0 for FY2025, 329.87% up from the prior year.
  • Non Operating Income for Q4 2025 was $5.9 million at Neuphoria Therapeutics, up from -$4.3 million in the prior quarter.
  • The five-year high for Non Operating Income was $5.9 million in Q4 2025, with the low at -$4.3 million in Q3 2025.